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Recent understandingofatherosclerosis andcoronaryheart diseasehas shiftedthefocus fromlumen stenosistovulnerableplaque,
from lipid deposit to inﬂammatory reaction, and from vulnerable plaque to vulnerable patient. This has led to a new direction
of treatment consisting of intervening the inﬂammatory reaction, stabilizing the vulnerable plaque, inhibiting thrombosis after
plaque rupture, and treating the vulnerable patient instead of treating lumen stenosis. This seems to mirror the traditional Chinese
medicine (TCM) focus on prevention and on the vulnerable patient with treatment matched to the pattern dysfunction and
dysregulation using the Chinese herbal medicine multitargeted approach. Given the convergence of both the East and the West
conceptualization of atherosclerosis, it is hopeful that the integrative East-West approach will facilitate early detection and more
eﬀective treatment of the vulnerable patients with coronary heart disease.
1.Introduction
Atherosclerosis (AS) is the most common type of arterioscle-
rosis. It mainly involves the large and middle muscular arter-
ies, especially aorta, coronary and cerebral arteries, which
oftenleadstoseriousoutcomessuchassuddencardiacdeath,
unstableanginapectoris,acutemyocardialinfarction,stroke,
and intermittent claudication due to vessel obliteration or
plaqueruptureandsubsequentthrombosis. Inthebeginning
of the 21st century, we are facing serious challenges of
cardiovascular disease (CVD). Although it is becoming less
lethal, CVD prevalence is incessantly increasing, and it is still
the most common cause of death. How to prevent AS and
reduce the incidence and mortality of CVD have been one of
the most important health-related issues all the time.
However, biomedicine is at its limits nowadays when
confronting degenerative diseases, stress-related diseases,
and most chronic diseases. It lacks reference to the self-
healing capacity of the human mind and body and focuses
on parts rather than the whole, treatment rather than
prevention, the suﬀering disease rather than the diseased
person.Confrontedwiththeseproblems,moreandmorefar-
sightedWesternscholarsbegantolaytheireyesontraditional
Chinese medicine (TCM) [1–3]. Drugs with Chinese herbal
medicines as raw materials are increasingly favored by
people all over the world for their unique advantages in
preventing and curing diseases, rehabilitation, and health
care. The beneﬁt of TCM in CVD was also demonstrated in
several multicenter clinical trials in recent years [4–7]. More
importantly,theuniquetheoryofTCMmightalsohavesome
implications for the renewal of thinking in ﬁghting against
CVD [8]. Therefore, we reviewed traditional understanding
and shifted concepts on AS pathophysiology along the track
of previous studies and read these transitions taking full
advantage of TCM theory together with our experimental
and clinical studies in recent years, so as to provide an
integrative East-West medicine perspective for future AS
prevention and treatment.
2. Updated Concept of Atherosclerosis
2.1. From Emphasizing “Luminal Stenosis” to Highlighting
“Vulnerable Plaques”. With the deep understanding and
active control of AS risk factors, dramatic advances have
been made in primary prevention of chronic cardiovascular
diseases since 1990s. However, there is still lack of eﬀective
measure to prevent acute cardiovascular events (ACEs),
which cause 20 million deaths worldwide per year. Most of
the victims die suddenly without any prior symptoms.
The previous studies focused on the severity of coro-
nary stenosis, taking coronary heart disease (CHD) as an2 Evidence-Based Complementary and Alternative Medicine
example of AS, and highlighted detection of severe luminal
stenosis and subsequent treatment of percutaneous coronary
intervention (PCI). The development or improvement of
coronary stenosis is also regarded as an important indicator
to evaluate the state of illness or therapeutic eﬀect. However,
angiographic studies on patients before myocardial infarc-
tion showed that the majority of subsequent events involved
sites with less than 70% obstruction. It indicated that the
severity of stenosis was not the main cause of ACEs [9].
In1989,Mullerandhiscolleaguesusedtheword“vulner-
able” to describe rupture-prone plaques, with characteristics
of a large lipid pool, a thin cap, and macrophage-dense
inﬂammation on or beneath its surface [10], as the underly-
ing cause of most clinical coronary events. More and more
studies suggested that ACEs were triggered by thrombosis
associated with rupture of vulnerable atherosclerotic plaques
[11]. The change of plaque from its stable state to an
unstable one was not related to the plaque size, quantity, or
position or the severity of stenosis. Although PCI improves
signiﬁcant stenosis, it cannot inﬂuence the biological course
of vulnerable plaque, thus the problem of “unstable” plaque
is still unresolved.
In recent years, many clinical trials showed that statins
couldreduceACEssigniﬁcantlyyetonlyimprovetheluminal
size slightly [12]. Experimental researches have proved that
statins have potential eﬀects on stability of AS plaques [13].
Stenting (including drug-eluting stents) reduces restenosis
and repeated intervention, but does not reduce mortality
or myocardial infarction [14]. Therefore, it is necessary for
us to reevaluate the beneﬁts of active medicinal treatment
and invasive PCI treatment in chronic myocardial ischemia.
Based on in-depth understanding of AS pathogenesis, the
vascular pathophysiological research has turned to new
direction of stabilizing vulnerable plaque and inhibiting
thrombosis after plaques rupture. The secondary prevention
of CHD also focused on intervention of vulnerable plaque
instead of treating luminal stenosis of coronary artery
[15, 16].
2.2. From Predominant Theory of “Lipid Deposit” to General
Acknowledgment of “Inﬂammatory Reaction” Theory. “Lipids
deposit”theoryofAShasbeenputforwardforover100years
based on the causal relation between hyperlipidemia and AS
[17]. This theory holds that lipids deposition on the artery
wall leads to the AS plaques and has played a very important
role in AS pathogenesis for a long period.
In recent years, some researches indicated that AS had
the basic manifestation of inﬂammation: degeneration, exu-
dation, and proliferation. The cell-cell interaction is similar
to other chronic inﬂammation diseases such as rheumatoid
arthritis, chronic pancreatitis, and hepatic cirrhosis. With
continuous detection of inﬂammatory cells and mediators,
AS was no longer regarded as a simple disease of lipid
depositiononvesselwallbutalsoanadvancinginﬂammatory
reaction. Recent advances in basic science have established a
fundamental role for inﬂammation in mediating all stages
of this diseases from initiation through progression and,
ultimately, the thrombotic complications of AS.
In 1999, based on his famous “injury reaction” theory,
Ross declared that AS is one of the inﬂammatory disease
[18]. AS is a process of active inﬂammatory reaction inside
the vessel wall rather than a process of passive lipid deposit
onto the vessel wall. This theory initiates a new epoch
of AS treatment and it leads to deep understanding of
cardiovascular diseases: inﬂammation fuels the development
and progression of atherosclerosis as well as causes certain
plaques to rupture and subsequent thrombosis, leading
to such atherosclerotic complications as heart attack and
stroke. High-sensitivity C-reactive protein (hs-CRP) and
other blood inﬂammatory markers may be useful in the
estimation of prognosis, risk level in AS patients, and even
be a potential target of AS treatment and prevention [19].
Despiteregulatingbloodlipidsmetabolism,statinsshouldbe
recommended for their anti-inﬂammation and other protec-
tive eﬀects on cardiovascular diseases. Aspirin can not only
inhibit platelet aggregation but also prevent the malfunction
of endothelial cells through its anti-inﬂammation eﬀects
[16]. Anti-inﬂammation has been one of the most important
issues of AS research and several strategies that intervene
with inﬂammation reaction are under study.
2.3. New Concept from “Vulnerable Plaque” to “Vulnerable
Patient”. Plaque rupture is the most common type of
plaque complication, accounting for nearly 70% of fatal
acutemyocardial infarctions and/or sudden coronarydeaths.
Vulnerable plaque is the main, but not the unique, cause for
ACEs. The position of plaque rupture, the size and amount
of plaques, coronary spasm, hypercoagulable state, collateral
circulation,andthedegreeofmyocardialdamageshouldalso
be considered. In 2003, an article named “From vulnerable
plaque to vulnerable patient: a call for new deﬁnitions and
risk assessment strategies” was published on Circulation
written by over ﬁfty of the most famous cardiovascular
expertsoftheworld[20,21].Thenewconceptof“vulnerable
plaque” to “vulnerable patients” has led in a new direction to
the prevention of ACEs.
The term “vulnerable patient” is proposed to deﬁne
subjects susceptible to an acute coronary syndrome or
sudden cardiac death based on plaque, blood, or myocardial
vulnerability (1-year risk ≥5%). Extensive eﬀorts are needed
to quantify an individual’s risk of an event according
to each component of vulnerability (plaque, blood, and
myocardium). Such a comprehensive risk-stratiﬁcation tool
capable of predicting acute coronary syndromes as well as
sudden cardiac death would be very useful for preventive
cardiology. The new concept of “vulnerable plaque” to “vul-
nerable patients” stresses evaluating patients as a whole and
thus further optimizes overall assessment of cardiovascular
risks, and prevents ACEs by early intervention of vulnerable
patients.
3.AnIntegrativeEast-WestMedicine
Perspectivefor FutureAS Management
The transitions in understanding AS, from local plaques to
entire coronary tree and patient as a whole, from passiveEvidence-Based Complementary and Alternative Medicine 3
lipid deposit process to an active inﬂammatory reaction and
cellinteractionprocess,innovatestrategiesofpreventionand
treatment for AS and CHD from coronary stenosis-targeted
invasive PCI treatment to vulnerable patient-targeted com-
prehensive assessment, early-detection and preventive medi-
cation strategies, happen to mirror “holism concept” “living
in harmony with the environment” “preventive treatment of
disease” and “treatment based on syndrome diﬀerentiation
or pattern diagnosis” advocated by TCM. They can also
help us fully understand the two diﬀerent medical systems,
Western medicine (WM) and TCM, as well as make the best
of the advantages of both of them.
The previous researches have shown that Chinese
medicines of activating blood circulation (ABC) could treat
AS by multiple ways such as lowering blood lipid, inhibiting
platelet adhesion and aggregation, and improving blood
viscosityandinhibitingSMCproliferation.In2003,basedon
AS models of ApoE-deﬁcient mice, we studied the eﬀects of
six ABC herbs (Radix Salviae Miltiorrhizae, Radix Paeoniae
Rubra, Rhizoma Chuanxiong, Radix Notoginseng, Semen
Persicae, Wine steamed Radix, and Rhizoma Rhei) and
a compound preparation (consisting of Chuanxingol and
Paeoniﬂorin) on stabilizing AS plaque and their potential
mechanisms. The results indicated that most ABC herbs
showed multiple eﬀects on diﬀerent links of AS, such as
regulating blood lipids, inﬂuencing collagen metabolism,
and anti-inﬂammatory reaction, thus had potential eﬀect on
stabilizing AS plaque [22, 23]. Although the ﬁnal eﬀect of
ABC herbs on stabilizing plaque was slightly less than that of
simvastatin, they showed better eﬀects on certain links such
as increasing high-density lipoprotein cholesterol (HDL-C),
which exhibited the superiorities of Chinese medicine in
overall regulation by inﬂuencing multiple targets [8]. The
superior eﬀect of the compound preparation to either herbal
extractive component [24] indicated the synergetic eﬀect
based on TCM compatibility theory. Therefore, Chinese
herbal medicines, especially compound prescriptions, war-
rantfurtherinvestigationandmightbeancomplementaryor
alternative therapy to statins in stabilizing vulnerable plaque
through a synergistic and multitargeted eﬀect.
The new concept of “vulnerable patient” also provides
TCM with new opportunity in detecting high-risk CHD
patients and further reducing ACEs by early intervention.
Under the guidance of TCM holism concept and thought of
treatment based on syndrome diﬀerentiation, we conducted
a multicenter cohort study, enrolling stable CHD patients
and documenting one-year follow-up cardiovascular end-
point events. Prognosis-related factors, including past med-
ical history, symptoms, body signs, biochemical indicators,
and tongue manifestations, were identiﬁed to establish an
integrative risk-assessment system for detecting high-risk
CHD patients [25–27]. A large-scale randomized controlled
trial aiming at early intervening high-risk CHD patients
based on this integrative risk assessment system is about
to start soon. Given the convergence of both the East and
the West conceptualization of AS, it is hopeful that this
integrative East-West strategy will facilitate early detection
and more eﬀective treatment for the vulnerable patients with
CHD and other AS-related diseases.
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